Eugene Garrison Dec/ 21/ 2018 | 0
The Andalusian School of Public Health, together with the Medical Oncology Service of the Virgen del Rocío Hospital and in collaboration with the Comprehensive Oncology Plan of Andalusia, have organized the VI Encuentro de trabajo sobre Immunooncología.
The VI meeting on Immunooncology, has analyzed with experts from different medical specialties, advances in immunotherapy in the treatment of some cancers and the challenge for the sustainability of the health system with the incorporation of these new treatments.
Immunotherapy, unlike chemotherapy and other systemic treatments, is a therapeutic strategy that enables the patient’s own immune system to fight against cancer cells. With this approach, new paradigms related to its mechanism of action have been established and are implicated in its potential long-term efficacy, new response assessment criteria, specific immune-mediated toxicities, biomarkers, synergies with other treatments (including “classical” therapies such as chemotherapy and radiotherapy) and a long etcetera.
This professional meeting is organized by the Andalusian School of Public Health (EASP) and the Medical Oncology Service of the Virgen del Rocío University Hospital of Seville in collaboration with the Comprehensive Plan of Oncology of Andalusia (PIOA), and has been held at the Institute of Biomedicine of Seville (IBis). The day was sponsored by the Bristol-Myers Squibb laboratory.
Immunotherapy against some cancers and evaluation of treatment efficiency
The work day has focused on two major blocks, immunotherapy as a therapeutic innovation in the National Health System (NHS) and the Andalusian Public Health System (SSPA) and immunotherapy as a treatment against cancer.
The identification of new biomarkers, immunotherapy in patients with advanced melanoma, in bladder and kidney tumors and in non-small cell lung cancer have been some of the topics of the first round table, which has focused on the study of advances in the field of Immunotherapy against cancer.
The evaluation of the efficiency in immuno-oncology, the access of the patients to the new treatments in oncology and the sustainability in the therapeutic innovation, have been the subjects that have been approached in the second table.
Immunotherapy in the treatment of cancer
One more year is reinforced, in view of the results achieved with immunotherapy in the treatment of some cancers (cutaneous melanoma, genitourinary tumors, lung …), the existence of a turning point in the fight against cancer and the need for a multidisciplinary coordination.
One of the objectives of the Comprehensive Oncology Plan of Andalusia (PIOA) is “to guarantee that those people who develop a cancer have a rapid and reliable diagnosis and that the treatment, support measures and care they receive are the most appropriate”, In line with this objective, the collaboration and support of PIOA is part of this Conference, which has celebrated its sixth edition.
From left to right, Reyes Bernabé, head of the section of Medical Oncology hospital Virgen del Rocío, Rafael Solana general secretary of Research, Development and Innovation in Health and María José Sánchez professor of the EASP and director of the Cancer Registry of the province of Granada